Advertisement
News
Advertisement

Karolinska Development to Divest Portfolio Company

Tue, 06/29/2010 - 10:38am
Bio-Medicine.Org

STOCKHOLM, June 29, 2010 /PRNewswire/ -- Today, Karolinska Development has divested Cogmed, one of Karolinska Development's portfolio companies, to Pearson where it will become part of Pearson's Clinical Assessment business. Karolinska Development and other owners will receive an up front payment, as well as tiered royalties up to double digit levels until June 2012 on Cogmed sales. Karolinska Development holds 51.83 percent of Cogmed. Pearson will take possession on June 29, 2010.

The financial details of the acquisition have not been disclosed.

Redwood Capital Group acted as exclusive financial advisor to Cogmed in connection with the transaction.

TO THE EDITORS

About Karolinska Development

Karolinska Development manages one of the largest portfolios of life science companies in Europe. Using a unique, highly cost efficient business model, the management team guides the commercialization of world class life science innovations, helping to shape the next generation Pharma industry. Since 2003, Karolinska Development has built a portfolio of some 40 companies; among the company's projects 12 compounds are undergoing clinical trials. The portfolio contains a total of 21 potential first-in-class products. http://www.karolinskadevelopment.com

About Cogmed

Cogmed was founded in 2001. The company provides scien

'/>"/>

SOURCE

Topics

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading